May 2, 2023 2:21 pm EDT

Organon continues its advocacy for the health and wellbeing of women with the launch of its Reflect Reconciliation Action Plan and new collaboration with Macquarie University’s Walanga Muru

SYDNEY, AUSTRALIA, 3 May 2023:
Organon Australia, a company dedicated to the health and wellbeing of women, today launched its first Reconciliation Action Plan (RAP), focused on supporting First Nations communities in health, spiritual wellbeing and caring for Country.

As a company that is focused on the health and wellbeing of women and guided by the belief that the health of women is foundational to the health of society, this first Reflect RAP seeks to embrace unity between Aboriginal and Torres Strait Islander peoples and other Australians, promote equality and equity in health and wellbeing for all, and acknowledge Australians’ shared history.

Endorsement of the RAP is a step in the journey, and Organon has already been working towards bringing their first RAP to life in practical ways.

“Organon is less than two years’ old, and one of the early conversations with employees in Australia was the about reconciliation with First Nations people and developing a Reconciliation Action Plan. Our first action on this journey was to demonstrate our commitment by signing the Statement from the Heart on National Sorry Day 2022”, said Nirelle Tolstoshev, Managing Director Organon Australia and New Zealand.

“In line with this, Organon is supporting a YES vote in the upcoming referendum for a Voice to Parliament, and we are working with our people to deepen their understanding regarding this important issue, ensuring their voices are heard, and respecting each employees’ right to make their own decisions.

“To mark this important milestone in Organon’s journey to reconciliation, and a demonstration of our organisations values, we are also pleased to announce a collaboration with Macquarie University and Walanga Muru”.

Walanga Muru supports positive Indigenous higher education reform through the establishment of structures, processes and relationships across the University to provide a framework to incorporate Indigenous perspectives into all aspects of the University now and into the future.

“Macquarie University is our local tertiary institution, and this partnership is further demonstration of our commitment to make a positive impact to healthy lifestyles, and advance equity through education and opportunity.”

Dr Leanne Holt, Pro Vice-Chancellor Indigenous Strategy, Macquarie University said, “Walanga Muru and Macquarie University are really excited to be partnering with wonderful organisations like Organon. It provides a great opportunity to build respectful and reciprocal relationships that can contribute to positive outcomes for our first Nations’ students and communities.”

In 2022, Organon employees also dedicated over 80 hours of volunteer leave to support Supply Nation’s flagship event for the Indigenous business sector – Connect – and look forward to supporting again at this year’s event in August.

“Organon is a workplace of inclusion and significant diversity, and we take action to live our values through our expertise in Women’s Health by raising awareness and understanding for our employees, by listening to and learning from First Nations mentors, and partnering with like-minded organisations to advance our vision,” said Meshlin Khouri, Organon’s Associate Director Policy and Communications, and Reconciliation Working Group lead.

To learn more about Organon, please visit http://www.organon.com/australia and connect with us on LinkedIn.

To learn more about Walanga Muru – Indigenous Students | MQ Sydney

About Organon
Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck& Co., Kenilworth, NJ, USA (NYSE: MRK) known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey, USA.